Close

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company Nov 8, 2019 08:03AM
Genomic Health (GHDX) Holders Approve Merger with Exact Sciences (EXAS) Nov 7, 2019 01:57PM
Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences Nov 7, 2019 01:55PM
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment Sep 30, 2019 09:00AM
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer Aug 21, 2019 08:00AM
View Older Stories

Jul 29, 2019 07:02AM Exact Sciences (EXAS) to combine with Genomic Health (GHDX) for $72/share in cash and stock transaction valued at $2.8 billion
Jul 29, 2019 07:01AM Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Jul 29, 2019 07:00AM Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
Jul 25, 2019 08:00AM Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
Jun 20, 2019 01:00PM German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
Jun 3, 2019 11:45AM Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit,
Jun 3, 2019 08:00AM Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
May 29, 2019 08:00AM Genomic Health to Present at the Jefferies 2019 Healthcare Conference
May 7, 2019 04:05PM Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
Apr 30, 2019 08:00AM Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
Mar 25, 2019 08:06AM Genomic Health (GHDX) Says Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score Tes
Mar 25, 2019 08:00AM New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
Feb 28, 2019 01:01AM Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
Feb 28, 2019 01:00AM Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
Feb 20, 2019 04:05PM Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
Feb 13, 2019 08:00AM Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
Feb 5, 2019 08:00AM Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Jan 7, 2019 08:00AM Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Dec 19, 2018 08:02AM Genomic Health (GHDX) NICE Expands Recommendation for Oncotype DX Breast Recurrence Score Test to More Patients with Early-Stage Breast Cancer
Dec 19, 2018 08:00AM NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
Dec 18, 2018 08:00AM Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 10, 2018 08:00AM Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or R
Dec 3, 2018 04:51PM Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
Nov 29, 2018 08:00AM New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the
Nov 19, 2018 08:00AM Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
Nov 8, 2018 08:00AM Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 6, 2018 04:05PM Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
Oct 30, 2018 08:00AM Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Oct 29, 2018 08:08AM Genomic Health (GHDX) Says Medicare Established Final Local Coverage Determination for Use of the Oncotype DX AR-V7 Nucleus Detect Test
Oct 29, 2018 08:00AM Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective Decembe
Oct 22, 2018 08:09AM Genomic Health (GHDX) Reports Multiple Studies Reinforcing Value of Oncotype DX Tests in Guiding Treatment for Breast & Prostate Cancer Patients
Oct 22, 2018 08:00AM Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
Oct 9, 2018 04:15PM New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
Sep 28, 2018 08:00AM New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS™) Test
Sep 12, 2018 08:00AM Epic Sciences Announces Completion of $52 Million Series E Financing
Sep 7, 2018 08:00AM German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Sep 6, 2018 01:01AM Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
Sep 6, 2018 01:00AM Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
Aug 2, 2018 04:05PM Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
Jul 26, 2018 08:00AM Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
Jun 28, 2018 11:00AM Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
Jun 3, 2018 07:30AM Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage B
May 30, 2018 08:00AM Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
May 21, 2018 08:11AM Genomic Health (GHDX) Highlights New Data Reinforcing Positive Impact of Oncotype DX Genomic Prostate Score
May 21, 2018 08:00AM New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score™ Test in Guiding Treatment Decisions
May 9, 2018 08:00AM Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
May 2, 2018 04:05PM Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
Apr 26, 2018 08:00AM Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018 08:00AM Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
Mar 30, 2018 08:00AM Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic
View Older Stories